BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission

POMPANO BEACH, Fla., July 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the filing of a Form 10 registration statement (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirmed its strategic decision to pursue a listing on the Nasdaq Stock Market (“Nasdaq”).